Look here, FDA: Eli Lilly touts Olumiant safety data for unapproved high dose

[cafead]

via The path to success for Eli Lilly and Incyte’s rheumatoid arthritis med Olumiant in the U.S. has been a precarious one, with the FDA repeatedly knocking the drug’s larger dose. Could new long-term safety data—and a potential label expansion—help turn the tide in its fight against megablockbuster Humira?

article source